“XELOX + Bevacizumab Compared to FOLFOX4 + Bevacizumab in First Line Metastatic Colorectal Cancer in a Non-Reimbursed Health Care System: A Cost Analysis”. Acta Medica Philippina 49, no. 2 (June 30, 2015). Accessed April 5, 2025. https://actamedicaphilippina.upm.edu.ph/index.php/acta/article/view/988.